• Product

    BATYLAC 1=4, powder for oral use

  • Authorisation

    Unlicensed medicine

  • Active ingredient

    Batylalcohol 250 mg

  • Indication

    Rhizomelic Chondrodysplasia Punctata (RCDP)

  • Storage condition

    Below 25 °C

BATYLAC is prescribed for children with Rhizomelic Chondrodysplasia Punctata (RCDP). This is a rare hereditary metabolic disorder.

Legal status

BATYLAC is an unlicensed medicine in the Netherlands. The Dutch Health Care Inspectorate (IGZ) has given permission for the supply.

BATYLAC is supplied “from-pharmacy-to-pharmacy” on named patient basis. An order signed by the pharmacist and a physician’s statement from the prescribing physician are required with every order.

Availability for (Hospital) Pharmacies

In the Netherlands, BATYLAC is supplied by ACE Apotheek. More information for (hospital) pharmacies in the Netherlands can be found on the website of ACE Apotheek.

(Hospital) Pharmacies outside the Netherlands that would like to know more about the availability of this product are welcome to contact us via our contact form.